China's WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), has broken ground on its new 13.5-hectare CRDMO centre in Tuas Biomedical Park, Singapore. The centre will provide integrated biologics research, development and manufacturing services. 

WuXi Biologics announced a $1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO centre will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion. It will add 120,000L of manufacturing capacity to WuXi Biologics’ global network, and is expected to employ 1,500 staff. 

The site will be equipped with WuXi Biologics’ proprietary technical platforms, along with industry-leading technologies such as single-use technology to provide clients with time- and cost-efficient services. In line with WuXi Biologics’ Environmental, Social and Governance strategy, the site will implement sustainable concepts in the design and construction of the center, deploy digital tools and build energy-saving facilities.

“WuXi Biologics Singapore CRDMO centre will strengthen Singapore’s biopharmaceutical sector, which comprises global healthcare companies operating industry leading manufacturing and R&D facilities, complemented by a strong local R&D and start-up ecosystem. This investment will create significant employment opportunities for Singaporeans, and spur collaborations between WuXi Biologics, our R&D institutions and startups to develop innovative therapeutics and novel modalities. Singapore continues to welcome global healthcare players seeking to innovate, manufacture and commercialise end-to-end solutions for clients worldwide”, said Png Cheong Boon, Chairman, Singapore Economic Development Board (EDB).